证券日报网讯1月8日，国药现代（600420）在互动平台回答投资者提问时表示，如有重大事项公司将及 时履行信息披露义务。请以公司后续公告及定期报告披露信息为准。 ...

Group 1 - The fentanyl concept index rose by 4.74%, ranking 6th among concept sectors, with 8 stocks increasing in value, including Botao Bio which hit a 20% limit up [1] - The leading stocks in the fentanyl sector included Dongfang Bio, Lingrui Pharmaceutical, and ST Renfu, which rose by 5.12%, 4.88%, and 2.26% respectively [1] Group 2 - The fentanyl concept sector saw a net inflow of 55 million yuan, with ST Renfu leading the inflow at 69.89 million yuan, followed by Guoyao Shares, Guoyao Modern, and Lingrui Pharmaceutical [2] - The net inflow ratios for ST Renfu, Guoyao Modern, and Guoyao Shares were 14.70%, 7.69%, and 5.96% respectively, indicating strong interest from major funds [3]

Group 1 - Guangdong Construction signed an EPC contract worth 416 million yuan, with a total construction area of 99,595.6 square meters and a construction period of 640 calendar days [1] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [2] - Jinbei Automotive signed a memorandum of understanding with E-Works to establish a research and development center for electric light commercial vehicles [3] Group 2 - Hongsheng Huayuan is expected to win approximately 569 million yuan in procurement projects from the State Grid, which represents about 5.61% of the company's projected revenue for 2024 [4] - Zhongding Co. plans to establish a joint venture for humanoid robot manufacturing with a registered capital of 50 million yuan [5] - Kede CNC's new factory in Shenyang is expected to achieve an annual production capacity of about 60 units [6] Group 3 - Hongbo Pharmaceutical's share transfer price is set at 25.27 yuan per share [7] - ST Jinglan plans to sign a letter of intent for the acquisition of Xinlian Environmental Technology Co., enhancing its core technology competitiveness [8][9] - Hato Co. announced the resignation of its general manager due to job relocation [10] Group 4 - Meibang Co. plans to apply for a new bank credit line of up to 160 million yuan [11] - Southern Media's general manager resigned due to job relocation [12] - Dalian Electric Porcelain's subsidiary is expected to win procurement projects from the State Grid worth approximately 70.7 million yuan [13] Group 5 - Sinopharm Modern's subsidiary received a drug registration certificate for a new medication [14] - ST Meigu plans to implement a capital reserve transfer to increase share capital, leading to a one-day stock suspension [15] - Ruisheng Intelligent confirmed a transaction of 152 million yuan for domestic computing equipment procurement [16] Group 6 - Jinguang Electric won three procurement packages from the State Grid, totaling 37.43 million yuan [17] - Guangju Energy increased its stake in Mawan Power to 14.42% by acquiring an 8% share for 680 million yuan [18][19] - ST Lingda announced a stock suspension due to capital reserve transfer related to its restructuring plan [20] Group 7 - Suli Co. plans to increase its investment in Suli Ningxia by 76.63 million yuan [21] - Dalian Shengya's subsidiary plans to reduce its registered capital by 32.37 million yuan [22] - Yinxin Technology received a cash dividend of 11.05 million yuan from its subsidiary [23] Group 8 - Haike New Source signed a three-year supply agreement for 270,000 tons of electrolyte materials [24] - Xinhua Medical received registration certificates for several medical devices [25] - Wantai Bio received a registration certificate for an HIV antibody testing kit [26] Group 9 - Beilu Pharmaceutical obtained a drug registration certificate for a new erectile dysfunction treatment [31] - Zhongwei Company is planning to issue shares to acquire assets, leading to a stock suspension [32] - Zhejiang Haideman plans to purchase land for strategic development, with a budget of up to 260 million yuan [33] Group 10 - Ningbo Ocean announced the resignation of its deputy general manager due to job adjustments [34] - Tongguang Cable is expected to win procurement projects from the State Grid worth over 139 million yuan [35]

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern indicates the approval of the drug Fumaric Acid Quetiapine Extended-Release Tablets by the National Medical Products Administration, highlighting a significant development in the treatment of mental health disorders [1] Group 1: Company Information - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has received the drug registration certificate for Fumaric Acid Quetiapine Extended-Release Tablets [1] - The drug is classified as an atypical antipsychotic, aimed at regulating brain nerve activity and primarily used for managing schizophrenia and bipolar disorder [1] Group 2: Industry Implications - Fumaric Acid Quetiapine Extended-Release Tablets are designed to stabilize mood, reduce hallucinations, and improve cognitive confusion, thereby assisting patients in regaining normal cognitive and social functions [1]

Core Viewpoint - China National Pharmaceutical Modern (国药现代) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, which may enhance its product portfolio and market position [1] Group 1: Company Overview - China National Pharmaceutical Modern's subsidiary, Shanghai Modern Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Fumaric Acid Quetiapine Sustained-Release Tablets [1] - As of the latest report, the company's market capitalization stands at 13.7 billion yuan [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of China National Pharmaceutical Modern is as follows: - Formulations account for 49.84% - Intermediates and raw materials account for 47.53% - Other businesses account for 2.44% - Health-related products account for 0.19% [1]

证券代码：600420 证券简称：国药现代 公告编号：2025-097 上海现代制药股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）收到国家药品监督管理局核准签发的富马酸喹 硫平缓释片《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 药品名称：富马酸喹硫平缓释片 证书编号：2025S03885 剂型：片剂 规格：300mg（按 C₂₁H₂₅N₃O₂S 计） 注册分类：化学药品 4 类 申请事项：药品注册（境内生产） 药品批准文号：国药准字 H20256352 上市许可持有人：国药集团工业有限公司 药品生产企业：国药集团工业有限公司 企业地址：北京市顺义区牛栏山镇牛汇南一街 6 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及市场情况 富马酸喹硫平缓释片是一种非典型抗精神病药物，是 ...

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern indicates that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Fumaric Acid Quetiapine Extended-Release Tablets, a novel atypical antipsychotic medication [1] Group 1 - Fumaric Acid Quetiapine Extended-Release Tablets are primarily used for the treatment of schizophrenia and bipolar disorder, helping to stabilize mood, reduce hallucinations, and improve cognitive function [1] - The total research and development investment for Fumaric Acid Quetiapine Extended-Release Tablets (300mg) by China National Pharmaceutical Group Industrial has reached approximately RMB 10.407 million (unaudited) [1]

Core Viewpoint - The announcement highlights that China National Pharmaceutical Group Modern (国药现代) has received approval from the National Medical Products Administration for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, indicating a significant advancement in the company's pharmaceutical offerings [1] Group 1 - The product, Fumaric Acid Quetiapine Sustained-Release Tablets, is classified as an atypical antipsychotic medication [1] - It is primarily used for the treatment of schizophrenia and bipolar disorder, aiming to stabilize mood, reduce hallucinations, and improve cognitive function [1] - The medication is designed to assist patients in regaining normal cognitive and social functions [1]

Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (国药工业), has received the drug registration certificate for Fumaric Acid Quetiapine Extended-Release Tablets from the National Medical Products Administration [1] Group 1 - The Fumaric Acid Quetiapine Extended-Release Tablets are classified as atypical antipsychotic medications [1] - This medication is primarily used for the treatment of schizophrenia and bipolar disorder, helping to stabilize mood, reduce hallucinations, and improve cognitive function [1] - The drug aims to assist patients in regaining normal cognitive and social abilities [1]

证券日报网讯 12月24日，国药现代发布公告称，公司2025年第三次临时股东会审议通过《关于变更经 营范围暨修订的议案》等多项议案。 （文章来源：证券日报） ...